Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Leap Therapeutics Inc LPTX

Healthcare Biotechnology
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic... see more

Recent & Breaking News (NDAQ:LPTX)

Leap Therapeutics Announces Pricing of $90 million of Common Stock and Pre-Funded Warrants

PR Newswire September 22, 2021

Leap Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

PR Newswire September 21, 2021

Leap Therapeutics Presents Updated Positive Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO Congress

PR Newswire September 16, 2021

Leap Therapeutics to Present New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO 2021 Congress

PR Newswire September 13, 2021

Leap Therapeutics to Participate at Two Upcoming Virtual Investor Conferences

PR Newswire September 7, 2021

Leap Therapeutics Reports Second Quarter 2021 Financial Results and Upcoming Data Presentation

PR Newswire August 13, 2021

Leap Therapeutics to Present at the ESMO 2021 Virtual Congress

PR Newswire July 26, 2021

Leap Therapeutics to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference

PR Newswire July 7, 2021

Leap Therapeutics to Present at Raymond James 2021 Virtual Human Health Innovation Conference

PR Newswire June 14, 2021

Leap Therapeutics Reports First Quarter 2021 Financial Results

PR Newswire May 14, 2021

Leap Therapeutics and Flagship Biosciences Develop Image Analysis RNAscope Assay for Prospective Trial Enrollment

PR Newswire May 12, 2021

Flagship Biosciences and Leap Therapeutics Announce Partnership and Approach Using RNAscope and Image Analysis for Patient Enrollment

PR Newswire April 12, 2021

Leap Therapeutics Announces Completion of Enrollment for First-Line Patient Cohort in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer

PR Newswire April 1, 2021

Leap Therapeutics Presents DKN-01 Clinical Data at the Society of Gynecologic Oncology 2021 Annual Meeting on Women's Cancer

PR Newswire March 22, 2021

Leap Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results

PR Newswire March 12, 2021

Leap Therapeutics to Present at Upcoming Virtual Investor Conferences

PR Newswire February 22, 2021

Leap Therapeutics to Present at H.C. Wainwright BioConnect 2021 Conference

PR Newswire January 6, 2021

Leap Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference

PR Newswire January 4, 2021

Leap Therapeutics Announces Publication of DKN-01 Mechanism of Action Data in Molecular Cancer Research

PR Newswire December 22, 2020

Leap Therapeutics to Participate at Piper Sandler 32nd Annual Virtual Healthcare Conference

PR Newswire November 23, 2020